Kekkaku(Tuberculosis)
Online ISSN : 1884-2410
Print ISSN : 0022-9776
ISSN-L : 0022-9776
USEFULNESS OF QuantiFERON®TB-2G IN CONTACT INVESTIGATION OF A TUBERCULOSIS OUTBREAK IN A UNIV E RSITY
Kazushi FUNAYAMAAiko TSUJIMOTOMasaaki MORIHiromi YAMAMOTOKeiko FUJIWARATomoyasu NISHIMURANaoki HASEGAWAItsuko HORIGUCHIToru MORIEiji MARUI
Author information
JOURNAL FREE ACCESS

2005 Volume 80 Issue 7 Pages 527-534

Details
Abstract

[Purpose] This study examined the usefulness of QuantiFERON®TB-2G (QFT) i. e., a novel technique for detecting tuberculosis infection based on the whole blood interferon-gamma response to specific antigens, in the investigation of a tuberculosis outbreak among university students.
[Subjects and Method] One university student was diagnosed as smear-positive pulmonary tuberculosis. In order to determine the extent of tuberculosis infection among contact students, tuberculin skin tests and QFT were performed on the close-contact group (220 people), as well as on the non-closecontact group (242 people).
[Results] Nine st udents were found to be TB either clinically or on the X-ray screening in the contact investigation. In the close-contact group, the QFT-positive rate was 32.7%. The proportion of those exhibiting tuberculin reactions with erythema diameters of 30 mm or larger was 57.7%. In the non-close-contact group, the QFT-positive rate was only 0.8%, as expected from the current healthy Japanese youths of this age. In contrast, strong tuberculin reactions with erythema of 30 mm or larger were seen in 18.2% in the latter group, most likely due to the previous history of BCG vaccination.
[Conclusion] QFT was clearly demonstrated to be a useful method for diagnosing tuberculosis infection, especially among subjects who show tuberculin reactivity due to past BCG vaccination. At the same time, the current criteria for the indication of chemoprophylaxis based on the strong tuberculin reaction were considered to be unreliable, causing many subjects with strong reactions to be given unnecessary preventive medications.

Content from these authors
© THE JAPANESE SOCIETY FOR TUBERCULOSIS
Previous article Next article
feedback
Top